Key Subcutaneous Immunoglobulin (SCIG) Market Trend for 2025-2034: Advancements In Subcutaneous Immunoglobulin Therapy For Primary Immunodeficiency Diseases

What Is the Future Outlook for the Subcutaneous Immunoglobulin (SCIG) Market's Size and Growth Rate?
There has been a rapid expansion in the subcutaneous immunoglobulin (SCIG) market size in the previous years. It's projected to swell from $12.72 billion in 2024 to $14.52 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 14.1%. The upsurge in the past era is credited to the heightened occurrence of immunodeficiency disorders, an increase in patient inclination towards home-based care, improved therapeutic effectiveness, an increase in awareness and diagnosis rates, and the growth in favorable reimbursement policies.

Expectations indicate a surge in the market size of subcutaneous immunoglobulin (SCIG) in the coming years. The growth projection is set at a compound annual growth rate (CAGR) of 13.7%, reaching a value of $24.29 billion by 2029. This surge within the projected period can be accredited to factors such as an increase in neurological disorders, rising cases of autoimmune diseases, heightened awareness and adoption of immunoglobulin treatments, as well as their growing utilization in neurology and dermatology, and overall expansion of healthcare facilities. Key trends within this forecast period encompass advancements in the systems of drug delivery, a growing demand for home-based infusion therapies, progress in antibody treatment, and innovative breakthroughs in both SCIG formulations and its implementation.

What Is Stimulating Growth in the Subcutaneous Immunoglobulin (SCIG) Market?
The surging prevalence of secondary immunodeficiency diseases is predicted to fuel the expansion of the subcutaneous immunoglobulin market. These diseases, resulting from an impaired immune system due to factors other than the immune system itself, are becoming more common due to an aging population, the use of immunosuppressive treatments, and exposure to environmental toxins. Subcutaneous immunoglobulin therapy, by supplying antibodies, lends strength to the compromised immune systems, particularly in chronic conditions like HIV or autoimmune diseases. This prevents infections and aids in maintaining immune function during treatment. In support of this, UK Health Security Agency, a UK-based government agency, recorded 3,805 new HIV diagnoses in England in 2022, marking a 22% increase from the previous year. Thus, the escalating prevalence of secondary immunodeficiency diseases is causing the subcutaneous immunoglobulin market to grow. An escalation in the cases of neurological disorders is another notable driver pushing forward the subcutaneous immunoglobulin market expansion. Neurological disorders, encompassing any disorder of the nervous system, such as acute spinal cord injury, Alzheimer's dementia, Amyotrophic Lateral Sclerosis (ALS), ataxia, brain tumors and so on, are on the rise due to aging populations, environmental toxins, genetic predispositions, and changes in lifestyle. Subcutaneous immunoglobulin therapy proves beneficial in addressing these disorders by providing antibodies that help regulate the immune response, diminish inflammation, and steadying neuromuscular junctions, potentially slowing down disease progression and enhancing symptoms. Validating this, the Alzheimer's Association, a US-based nonprofit voluntary health organization, revealed that 6.5 million Americans aged 65 and older are currently diagnosed with Alzheimer's dementia, with estimates suggesting that this number could scale up to 13.8 million by 2060. Therefore, the spiking number of neurological disorders is motivating the growth of the subcutaneous immunoglobulin market.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15935&type=smp

Which Key Market Leaders Are Driving Subcutaneous Immunoglobulin (SCIG) Industry Growth?
Major companies operating in the subcutaneous immunoglobulin (SCIG) market are Pfizer Inc., Johnson & Johnson, Prothena Corporation plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Amgen Inc., Baxter International Inc., CSL Behring, Lonza Group, Grifols S.A., Octapharma AG, Dr. Reddy's Laboratories, Intas pharmaceutical Ltd., Emergent BioSolutions Inc., Kedrion Biopharma, LFB group, Biotest AG, Argenx SE, Bio Products Laboratory Ltd., ADMA Biologics Inc., Sino Biological Inc., Bharat Serums and Vaccines Limited (BSV), Kamada Pharmaceuticals, CinnaGen Co., Shire plc

What Are the Emerging Trends in the Subcutaneous Immunoglobulin (SCIG) Industry?
Prominent firms in the subcutaneous immunoglobulin market are progressing in the creation of subcutaneous human-klhw, a distinct mixture that has human immune globulins (Ig) that aids in fortifying the immune system. Subcutaneous human-klhw is designed for subcutaneous use and aimed at managing primary immunodeficiency diseases in humans. For example, in March 2022, Grifols S.A., a pharmaceutical corporation based in Spain, introduced XEMBIFY 20% subcutaneous immunoglobulin (SCIG). This is particularly intended to handle primary immunodeficiency, addressing a substantial medical requirement for individuals with compromised immunity. XEMBIFY is a ready-to-use mix that makes the treatment procedure more straightforward and enhances patient convenience. It remains stable at room temperature for up to 24 months, eliminating the necessity for refrigeration during storage and transport, highly beneficial in different healthcare environments.

What Are the Main Segments in the Subcutaneous Immunoglobulin (SCIG) Market?
The subcutaneous immunoglobulin (SCIG) market covered in this report is segmented -

1) By Product Type: Immunoglobulin A (IgA), Immunoglobulin G (IgG), Immunoglobulin M (IgM)
2) By Application: Primary Immunodeficiency Disorders, Autoimmune Diseases, Neurological Disorders, Other Applications
3) By End-Use: Clinics, Hospitals, Homecare, Other End-Uses

Subsegments:
1) By Immunoglobulin A (IgA): IgA1, IgA2
2) By Immunoglobulin G (IgG): IgG1, IgG2, IgG3, IgG4
3) By Immunoglobulin M (IgM): Pentameric IgM, Hexameric IgM

Pre-Book Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/subcutaneous-immunoglobulin-scig-global-market-report

Which Geographic Area Leads the Subcutaneous Immunoglobulin (SCIG) Market?
North America was the largest region in the subcutaneous immunoglobulin market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the subcutaneous immunoglobulin (SCIG) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

What Is Covered In The Subcutaneous Immunoglobulin (SCIG) Global Market Report?

- Market Size Analysis: Analyze the Subcutaneous Immunoglobulin (SCIG) Market size by key regions, countries, product types, and applications.
- Market Segmentation Analysis: Identify various subsegments within the Subcutaneous Immunoglobulin (SCIG) Market for effective categorization.
- Key Player Focus: Focus on key players to define their market value, share, and competitive landscape.
- Growth Trends Analysis: Examine individual growth trends and prospects in the Market.
- Market Contribution: Evaluate contributions of different segments to the overall Subcutaneous Immunoglobulin (SCIG) Market growth.
- Growth Drivers: Detail key factors influencing market growth, including opportunities and drivers.
- Industry Challenges: Analyze challenges and risks affecting the Subcutaneous Immunoglobulin (SCIG) Market.
- Competitive Developments: Analyze competitive developments, such as expansions, agreements, and new product launches in the market.

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=15935

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.